These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 9758283)

  • 21. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
    Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
    Yamaguchi K; Miyazaki S; Kashitani F; Iwata M; Kanda M; Tsujio Y; Okada J; Tazawa Y; Watanabe N; Uehara N; Igari J; Oguri T; Kaimori M; Kawamura C; Iinuma Y; Nisawataira T; Tashiro H; Ueno K; Ishigo S; Yasujima M; Kawahara S; Itoh C; Yoshida T; Yamanaka K; Toyoshima S; Katoh J; Kudoh M; Matsushima T; Niki Y; Miyashita N; Funato T; Kaku M; Sato N; Saito Y; Ishii K; Kuwabara M; Hongo T; Negayama K; Kamihira S; Miyazaki Y; Takii M; Ishii M; Nakagawa K; Ono J; Takada T; Murakami N; Taira M; Tamaki I; Matsudou Y; Nakasone I
    Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
    Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trovafloxacin: a new fluoroquinolone.
    Alghasham AA; Nahata MC
    Ann Pharmacother; 1999 Jan; 33(1):48-60. PubMed ID: 9972385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
    Girard AE; Girard D; Gootz TD; Faiella JA; Cimochowski CR
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2210-6. PubMed ID: 8619569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.
    Baquero F; Cantón R
    J Antimicrob Chemother; 1996 May; 37 Suppl A():1-18. PubMed ID: 8737121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
    Isenberg HD; Alperstein P; France K
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microbiology of newer fluoroquinolones: focus on respiratory pathogens.
    Jones RN
    Diagn Microbiol Infect Dis; 2002 Nov; 44(3):213-20. PubMed ID: 12493166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of temafloxacin against respiratory pathogens.
    Swanson RN; Hardy DJ; Chu DT; Shipkowitz NL; Clement JJ
    Antimicrob Agents Chemother; 1991 Mar; 35(3):423-9. PubMed ID: 2039192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae.
    Klugman KP; Gootz TD
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():51-5. PubMed ID: 9222070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
    Endtz HP; Mouton JW; den Hollander JG; van den Braak N; Verbrugh HA
    Antimicrob Agents Chemother; 1997 May; 41(5):1146-9. PubMed ID: 9145886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
    Lopez H; Stepanik D; Vilches V; Scarano S; Sarachian B; Mikaelian G; Finlay J; Sucari A
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of in-vitro and in-vivo antibacterial activity of tosufloxacin tosilate.
    Yamaguchi K
    J Infect Chemother; 2001 Dec; 7(4):205-17. PubMed ID: 11810586
    [No Abstract]   [Full Text] [Related]  

  • 35. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH
    Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.
    Cormican MG; Jones RN
    Antimicrob Agents Chemother; 1997 Jan; 41(1):204-11. PubMed ID: 8980783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
    Blondeau JM; Hansen G; Metzler KL; Borsos S; Irvine LB; Blanco L
    Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
    Jones RN; Pfaller MA
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
    Soussy CJ; Nguyen J; Goldstein F; Dabernat H; Andremont A; Leclercq R; Drugeon H; Cavallo P; Chardon H; Etienne J; Rio Y; Courvalin P
    Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.